Ultralife Corp Files 10-K/A Amendment for Fiscal Year Ended December 31, 2023

TL;DR

<b>Ultralife Corporation has filed an amendment to its 2023 10-K report, providing updated financial and operational disclosures.</b>

AI Summary

ULTRALIFE CORP (ULBI) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Ultralife Corporation filed an amended 10-K report for the fiscal year ending December 31, 2023. The filing is an amendment (No. 1) to the original 10-K report. The company's common stock is registered on NASDAQ under the trading symbol ULBI. Ultralife Corporation is incorporated in Delaware. The principal executive offices are located at 2000 Technology Parkway, Newark, NY 14513.

Why It Matters

For investors and stakeholders tracking ULTRALIFE CORP, this filing contains several important signals. This amendment suggests that the company is making corrections or providing additional information to its previously filed annual report, which could impact investor understanding of its financial health and strategic direction. The filing confirms Ultralife's listing on NASDAQ, providing a key identifier for investors tracking the company's stock performance.

Risk Assessment

Risk Level: low — ULTRALIFE CORP shows low risk based on this filing. The filing is an amendment to a 10-K, which typically indicates corrections or additions to previously reported information, but does not inherently signal significant new risks or positive developments without further detail.

Analyst Insight

Review the specific changes and additions made in this 10-K/A filing to understand any material updates to Ultralife Corp's financial position, operations, or risk factors.

Key Numbers

• 20231231 — Fiscal Year End (For the fiscal year ended December 31, 2023)
• 0-20852 — Commission File Number (Commission file number 0-20852)
• 16-1387013 — I.R.S. Employer Identification No. (I.R.S. Employer Identification No.)
• 0.10 — Par Value per Share (Common Stock, $0.10 par value per share)

Key Players & Entities

• ULTRALIFE CORP (company) — Exact name of registrant as specified in its charter
• ULBI (company) — Trading Symbol
• NASDAQ (company) — Name of each exchange on which registered
• Delaware (company) — State or other jurisdiction of incorporation of organization
• 2000 Technology Parkway (company) — Address of principal executive offices
• Newark (company) — City, State of principal executive offices
• NY (company) — State of principal executive offices
• 14513 (company) — Zip Code of principal executive offices

FAQ

Industry Context

Ultralife Corporation operates in the Miscellaneous Electrical Machinery, Equipment & Supplies industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 13 or 15(d).

What Investors Should Do

1. Analyze the specific amendments made in the 10-K/A filing.
2. Verify the accuracy of financial data and disclosures.
3. Assess any new or revised risk factors presented in the amendment.

Year-Over-Year Comparison

This is an amended filing (10-K/A), indicating updates or corrections to a previously submitted annual report for the fiscal year ended December 31, 2023.

Key Financial Figures

• $0.10 — ection 12(b) of the Act: Common Stock, $0.10 par value per share ULBI NASDAQ (

Filing Documents

• ulbi20231231_10ka.htm (10-K/A) — 413KB
• ex_658207.htm (EX-31.3) — 5KB
• ex_658198.htm (EX-31.4) — 5KB
• 0001437749-24-013405.txt (&nbsp;) — 670KB
• ulbi-20231231.xsd (EX-101.SCH) — 3KB
• ulbi-20231231_def.xml (EX-101.DEF) — 17KB
• ulbi-20231231_lab.xml (EX-101.LAB) — 23KB
• ulbi-20231231_pre.xml (EX-101.PRE) — 18KB
• ulbi20231231_10ka_htm.xml (XML) — 8KB

Executive Compensation

Executive Compensation 6 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 14 Item 13. Certain Relationships and Related Transactions, and Director Independence 16 Item 14. Principal Accountant Fees and Services 17 PART IV Item 15. Exhibits, Financial Statement Schedules 18 Exhibit Index 19

Signatures

Signatures 21 PART III

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Directors The following sets forth certain information concerning our directors as of April 24, 2023. Name Age Present Principal Occupation, Employment History and Expertise Michael E. Manna 54 Mr. Manna has served as our President and Chief Executive Officer and as a director of the Company since November 22, 2022. Mr. Manna has almost thirty years' experience in the battery industry, all with Ultralife Corporation. He joined the Company in 1993 and held numerous leadership positions of increasing responsibility in engineering, operations, product management, research & development and sales. Most recently, Mr. Manna served as President, Battery & Energy Products and continues in his leadership of this business segment. Mr. Manna is a well-recognized expert in rechargeable and primary battery cell design across multiple chemistries in both commercial and government/defense markets. He has been awarded several patents for the Company and was a key member of the team that delivered the first Lithium-Ion Polymer Cell to the market. Mr. Manna has a BS degree in Computer Science from Rochester Institute of Technology. Mr. Manna has been nominated for election to our Board of Directors because of his battery industry expertise and his demonstrated leadership as President and Chief Executive Officer of the Company. Janie Goddard 53 Ms. Goddard has been a director of the Company since February 21, 2023. Since October 2023, Janie has served as the CEO of ICM Controls Corporation, an advanced manufacturing company. ICM provides electronic controls, components, and sub-systems for industrial applications. Prior to ICM, Ms. Goddard served as a Divisional Chief Executive for the Environmental and Analysis Sector at Halma plc, a global group of technology companies and as a Divisional Chief Executive of Halma's Medical and Environmental Sector from 2019 - 2023. Prior to Halma, Ms. Goddard served in

View Full Filing

View this 10-K/A filing on SEC EDGAR